Uridine prevents tamoxifen-induced liver lipid droplet accumulation

BMC Pharmacology and Toxicology

Volumn 15, Issue 1, 2014, Pages

  Le, Thuc T ^a,b,c   Urasaki, Yasuyo ^a,b,c   Pizzorno, Giuseppe ^a,b  

^a NEVADA CANCER INSTITUTE   (United States)

^b DESERT RESEARCH INSTITUTE   (United States)

^c ROSEMAN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Coherent anti Stokes Raman scattering microscopy; Drug induced fatty liver; Lipidomics; Membrane phospholipid; Mitochondrial respiration; Protein lysine acetylation; Pyrimidine; Tamoxifen; Triacylglyceride; Uridine phosphorylase

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MEMBRANE PHOSPHOLIPID; PYRIMIDINE; TAMOXIFEN; TRIACYLGLYCEROL; URIDINE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; LIPID; PROTECTIVE AGENT; URIDINE PHOSPHORYLASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; FATTY LIVER; LIPID LIVER LEVEL; LIPID METABOLISM; LIPID STORAGE; LIVER CELL; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; OXYGEN CONSUMPTION; PHOSPHOLIPID SYNTHESIS; PROTEIN ACETYLATION; ANIMAL; BLOOD; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEMALE; GENETICS; LIVER; METABOLISM; TRANSGENIC MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; FATTY LIVER; FEMALE; LIPID METABOLISM; LIPIDS; LIVER; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROTECTIVE AGENTS; TAMOXIFEN; URIDINE; URIDINE PHOSPHORYLASE;

EID: 84906926491     PISSN: None     EISSN: 20506511     Source Type: Journal    
DOI: 10.1186/2050-6511-15-27     Document Type: Article

References (37)

1. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 1998, 90(18):1371-1388.
2. Hackshaw A, Roughton M, Forsyth S, Monson K, Reczko K, Sainsbury R, Baum M: Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer. J Clin Oncol 2011, 29(13):1657-1663.
3. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska, Kwan WH, Matthew BS, Mittra I, Muller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, et al: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013, 381(9869):805-816.
4. Nishino M, Hayakawa K, Nakamura Y, Morimoto T, Mukaihara S: Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy. AJR Am J Roentgenol 2003, 180(1):129-134.
5. Ogawa Y, Murata Y, Nishioka A, Inomata T, Yoshida S: Tamoxifen-induced fatty liver in patients with breast cancer. Lancet 1998, 351(9104):725.
6. Nguyen MC, Stewart RB, Banerji MA, Gordon DH, Kral JG: Relationships between tamoxifen use, liver fat and body fat distribution in women with breast cancer. Int J Obes Relat Metab Disord 2001, 25(2):296-298.
7. Cohen JC, Horton JD, Hobbs HH: Human fatty liver disease: old questions and new insights. Science 2011, 332(6037):1519-1523.
8. Bruno S, Maisonneuve P, Castellana P, Rotmensz N, Rossi S, Maggioni M, Persico M, Colombo A, Monasterolo F, Casadei-Giunchi D, Desiderio F, Stroffolini T, Sacchini V, Decensi A, Veronesi U: Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ 2005, 330(7497):932.
9. Cardoso CM, Custodio JB, Almeida LM, Moreno AJ: Mechanisms of the deleterious effects of tamoxifen on mitochondrial respiration rate and phosphorylation efficiency. Toxicol Appl Pharmacol 2001, 176(3):145-152.
10. Lelliott CJ, Lopez M, Curtis RK, Parker N, Laudes M, Yeo G, Jimenez-Linan M, Grosse J, Saha AK, Wiggins D, Hauton D, Brand MD, O'Rahilly S, Griffin JL, Gibbons GF, Vidal-Puig A: Transcript and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic steatosis. FASEB J 2005, 19(9):1108-1119.
11. Larosche I, Letteron P, Fromenty B, Vadrot N, Abbey-Toby A, Feldmann G, Pessayre D, Mansouri A: Tamoxifen inhibits topoisomerases, depletes mitochondrial DNA, and triggers steatosis in mouse liver. J Pharmacol Exp Ther 2007, 321(2):526-535.
12. Gudbrandsen OA, Rost TH, Berge RK: Causes and prevention of tamoxifeninduced accumulation of triacylglycerol in rat liver. J Lipid Res 2006, 47(10):2223-2232.
13. Lebrecht D, Vargas-Infante YA, Setzer B, Kirschner J, Walker UA: Uridine supplementation antagonizes zalcitabine-induced microvesicular steatohepatitis in mice. Hepatology 2007, 45(1):72-79.
14. Le TT, Urasaki Y, Pizzorno G: Uridine prevents fenofibrate-induced fatty liver. PLoS One 2014, 9(1):e87179.
15. Connolly GP, Duley JA: Uridine and its nucleotides: biological actions, therapeutic potentials. Trends Pharmacol Sci 1999, 20(5):218-225.
16. Pizzorno G, Cao D, Leffert JJ, Russell RL, Zhang D, Handschumacher RE: Homeostatic control of uridine and the role of uridine phosphorylase: a biological and clinical update. Biochim Biophys Acta 2002, 1587(2-3):133-144.
17. Cao D, Leffert JJ, McCabe J, Kim B, Pizzorno G: Abnormalities in uridine homeostatic regulation and pyrimidine nucleotide metabolism as a consequence of the deletion of the uridine phosphorylase gene. J Biol Chem 2005, 280(22):21169-21175.
18. Le TT, Ziemba A, Urasaki Y, Hayes E, Brotman S, Pizzorno G: Disruption of uridine homeostasis links liver pyrimidine metabolism to lipid accumulation. J Lipid Res 2013, 54(4):1044-1057.
19. Gasser T, Moyer JD, Handschumacher RE: Novel single-pass exchange of circulating uridine in rat liver. Science 1981, 213(4509):777-778.
20. Urasaki Y, Johlfs MG, Fiscus RR, Le TT: Imaging immune and metabolic cells of visceral adipose tissues with multimodal nonlinear optical microscopy. PLoS One 2012, 7(6):e38418.
21. Le TT, Ziemba A, Urasaki Y, Brotman S, Pizzorno G: Label-free evaluation of hepatic microvesicular steatosis with multimodal coherent anti-stokes Raman scattering microscopy. PLoS One 2012, 7(11):e51092.
22. Evans CL, Xie XS: Coherent anti-Stokes Raman scattering microscopy: chemically selective imaging for biology and medicine. Annu Rev Anal Chem 2008, 1(1):883-909.
23. Le TT, Yue S, Cheng JX: Shedding new light on lipid biology with coherent anti-Stokes Raman scattering microscopy. J Lipid Res 2010, 51(11):3091-3102.
24. Zhang J, Nuebel E, Wisidagama DR, Setoguchi K, Hong JS, Van Horn CM, Imam SS, Vergnes L, Malone CS, Koehler CM, Teitell MA: Measuring energy metabolism in cultured cells, including human pluripotent stem cells and differentiated cells. Nat Protoc 2012, 7(6):1068-1085.
25. Robinson SP, Langan-Fahey SM, Johnson DA, Jordan VC: Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab Dispos 1991, 19(1):36-43.
26. Pezacki JP, Blake JA, Danielson DC, Kennedy DC, Lyn RK, Singaravelu R: Chemical contrast for imaging living systems: molecular vibrations drive CARS microscopy. Nat Chem Biol 2011, 7(3):137-145.
27. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ, Nonalcoholic Steatohepatitis Clinical Research Network: Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41(6):1313-1321.
28. Garcia Urena MA, Colina Ruiz-Delgado F, Moreno Gonzalez E, Jimenez Romero C, Garcia Garcia I, Loinzaz Segurola C, Gonzalez P, Gomez Sanz R: Hepatic steatosis in liver transplant donors: common feature of donor population? World J Surg 1998, 22(8):837-844.
29. Markin RS, Wisecarver JL, Radio SJ, Stratta RJ, Langnas AN, Hirst K, Shaw BW Jr: Frozen section evaluation of donor livers before transplantation. Transplantation 1993, 56(6):1403-1409.
30. El-Badry AM, Breitenstein S, Jochum W, Washington K, Paradis V, Rubbia-Brandt L, Puhan MA, Slankamenac K, Graf R, Clavien PA: Assessment of hepatic steatosis by expert pathologists: the end of a gold standard. Ann Surg 2009, 250(5):691-697.
31. Kendrick AA, Choudhury M, Rahman SM, McCurdy CE, Friederich M, Van Hove JL, Watson PA, Birdsey N, Bao J, Gius D, Sack MN, Jing E, Kahn CR, Friedman JE, Jonscher KR: Fatty liver is associated with reduced SIRT3 activity and mitochondrial protein hyperacetylation. Biochem J 2011, 433(3):505-514.
32. Hirschey MD, Shimazu T, Jing E, Grueter CA, Collins AM, Aouizerat B, Stancakova A, Goetzman E, Lam MM, Schwer B, Stevens RD, Muehlbauer MJ, Kakar S, Bass NM, Kuusisto J, Laakso M, Alt FW, Newgard CB, Farese RV Jr, Kahn CR, Verdin E: SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol Cell 2011, 44(2):177-190.
33. Kent C: Eukaryotic phospholipid biosynthesis. Annu Rev Biochem 1995, 64:315-343.
34. Cao D, Ziemba A, McCabe J, Yan R, Wan L, Kim B, Gach M, Flynn S, Pizzorno G: Differential expression of uridine phosphorylase in tumors contributes to an improved fluoropyrimidine therapeutic activity. Mol Cancer Ther 2011, 10(12):2330-2339.
35. Cai J, Lee CW: Tamoxifen inhibits nitrobenzylthioinosine-sensitive equilibrative uridine transport in human MCF-7 breast cancer cells. Biochem J 1996, 320(Pt 3):991-995.
36. Traut TW, Jones ME: Uracil metabolism-UMP synthesis from orotic acid or uridine and conversion of uracil to beta-alanine: enzymes and cDNAs. Prog Nucleic Acid Res Mol Biol 1996, 53:1-78.
37. Pizzorno G, Yee L, Burtness BA, Marsh JC, Darnowski JW, Chu MY, Chu SH, Chu E, Leffert JJ, Handschumacher RE, Calabresi P: Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor. Clin Cancer Res 1998, 4(5):1165-1175.